Affiliation:
1. Memorial Healthcare, Division of Hematology and Oncology, Pembroke Pines, FL 33028, USA
Abstract
Sarcomas are a group of malignancies of mesenchymal origin with a plethora of subtypes. Given the sheer heterogeneity of various subtypes and the rarity of the disease, the management of sarcomas has been challenging, with poor patient outcomes. Surgery, radiation therapy and chemotherapy have remained the backbone of treatment in patients with sarcoma. The introduction of immunotherapy has revolutionized the treatment of various solid and hematological malignancies. In this review, we discuss the basics of immunotherapy and the immune microenvironment in sarcomas; various modalities of immunotherapy, like immune checkpoint blockade, oncolytic viruses, cancer-targeted antibodies, vaccine therapy; and adoptive cell therapies like CAR T-cell therapy, T-cell therapy, and TCR therapy.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference122 articles.
1. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook;Banks;J. Natl. Compr. Cancer Netw.,2022
2. The 2020 WHO Classification of Soft Tissue Tumours: News and perspectives;Sbaraglia;Pathol. J. Ital. Soc. Anat. Pathol. Diagn. Cytopathol.,2020
3. Savina, M., Le Cesne, A., Blay, J.Y., Ray-Coquard, I., Mir, O., Toulmonde, M., Cousin, S., Terrier, P., Ranchere-Vince, D., and Meeus, P. (2017). Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: The METASARC observational study. BMC Med., 15.
4. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology;Kane;J. Natl. Compr. Cancer Netw.,2022
5. Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study;Penel;J. Clin. Oncol.,2008